doctor sikiric bpc-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded Form:Capsules The FDA panel just OCU

doctor sikiric bpc-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next. — WellFounded Form:Capsules The FDA panel just OCU

The FDA panel just voted to recommend BPC-157 and KPV for legal compounding. A first step toward regulated access — not final approval, but the clearest signal yet these peptides are moving

Short answer Fewer than 30% of researchers using BPC-157 choose their injection route deliberately

OCU

Form:Capsules

In this scenario, we reviewed the state-of-the-art on thymosins and MS, with particular attention to the neuroprotective and remyelinating action of Tβ4 and to the more recently characterized anti-inflammatory activity of Tα1